No Data
No Data
Hunan Fangsheng Pharmaceutical (603998.SH): Traditional Chinese medicine Xuanqi Jianbone tablets and children's Jingxing Antitussive granules have shown good development momentum in the first quarter.
Hunan Fangsheng Pharmaceutical (603998.SH) disclosed its investor relations activity record, which showed that the innovative traditional Chinese medicine Xuanqi Jiangu片 and the pediatric Jingxing Zhike granules had good development momentum in the first quarter. The hospitalization situation in the first half of the year basically met the company's expectations, and the specific sales income is still under statistics. During the research and development of innovative traditional Chinese medicine, through phase II and phase III clinical trials, there is sufficient evidence of syndrome-based medicine. With the continuous increase in coverage and market recognition, it is expected to achieve steady growth according to the company's development expectations.
Hunan Fangsheng Pharmaceutical (603998.SH): Currently, there are 13 research and development projects of innovative drugs in traditional Chinese medicine that have been carried out in pre-clinical studies.
Hunan Fangsheng Pharmaceutical (603998.SH) disclosed that a total of 13 preclinical research and development projects of innovative drugs based on traditional Chinese medicine have been launched, covering departments such as gynecology, orthopedics, respiratory, pediatrics, and oncology. In addition, the leading varieties with advanced progress among innovative traditional Chinese medicine drugs research and development projects are Nolitong granules, Jianwei Qutong pills, and Zhilong Tongluo tablets.
Hunan Fangsheng pharmaceuticals (603998.SH): at present, the overall channel inventory maintains a benign state.
According to the investor relations activity record of Hunan Fangsheng Pharmaceutical (603998.SH) disclosed by Gelonhui on July 19, the company timely adjusts production and inventory plans based on sales feedback from sales terminals, ensuring that inventory is always maintained at a relatively reasonable level, guaranteeing stable supply and meeting market demand. Currently, the overall channel inventory is in a good condition.
Hunan Fangsheng Pharmaceutical's (SHSE:603998) 29% CAGR Outpaced the Company's Earnings Growth Over the Same Three-year Period
Hunan Fangsheng Pharmaceutical (603998.SH): plans to establish a project subsidiary Fangsheng Rongke with affiliated party Xinyuan Chan Investment.
On July 8th, Gelonhui reported that Hunan Fangsheng Pharmaceutical (603998.SH) announced the development strategy of the company in the South China Greater Bay Area concept. With favorable conditions such as talent resources, policy environment in the Greater Bay Area, the company promotes the research and development progress of the Chinese patent medicine project, accelerates the incubation of innovative traditional Chinese medicine, and reasonably diversifies the risk of pharmaceutical research and development. The company intends to jointly invest with related party Xinyuanchantu to establish a project subsidiary company Fangshengrongke. Fangshengrongke mainly focuses on the exploration and incubation of innovative Chinese patent medicine, with a registered capital of 20 million yuan, of which the company intends to contribute 11 million yuan of self-owned funds, accounting for 55%; Xinyuanchantu
Hunan Fangsheng Pharmaceutical (603998.SH): Its subsidiary's traditional chinese medicine innovative drug research and development project has obtained a drug clinical trial approval notice.
Fangsheng Pharmaceutical (603998.SH) announced on July 5th that its subsidiary, Guangdong Fangsheng Rongda Pharmaceutical Co., Ltd. (hereinafter referred to as "Fangsheng Rongda"), received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for its traditional Chinese medicine innovative drug research and development project, the Benefiting Qi and Suppressing Tumor Granules.
No Data